In this Issue: 

• Almac Discovery announce licensing agreement with Debiopharm International SA
• Discover more about our recent analytical facilities expansion 
• Register for our complimentary Product Launch Workshop
  
• Download our Supply Chain Management eBook
• Access our latest article on Inspection Ready IRT
• Access our webinar on NGS Panels – From patient selection to CDx

Almac Discovery and Debiopharm International SA announce a licensing agreement for the development of a Novel Wee-1 Inhibitor

Under the terms of the license agreement, Almac Discovery has granted exclusive global rights to its Wee-1 patent families and related subject matter expertise to Debiopharm International SA.

Dr Stephen Barr, Managing Director & President, Almac Discovery commented “We are extremely pleased to announce this agreement with Debiopharm who have proven expertise and an impressive track record of developing drug candidates."

Analytical facilities expand to meet client demand

The facility has been inspected by the MHRA who confirmed a GMP certificate will be awarded. It includes equipment which has been relocated from existing laboratories, in addition to new equipment purchased to meet the demands of increasing capacity requirements. The new laboratory is an expansion of our existing laboratories which will remain in use to support analytical development activities.  

 
Almac Pharma Services to host complimentary EU Product Launch workshop in San Diego & Boston

A number of Almac’s subject matter experts will join key thought leaders from McGee Pharma, Vertex, Seattle Genetics and other industry experts to share real world experiences and provide unique advice regarding the complexities surrounding the launch of a product into the European market. 

The workshops will take place on 26^th September 2017 in San Diego and 28^th September 2017 in Boston. 

Almac launch part 3 of its Clinical Supply Knowledge Share eBook series

The increasing complexity of global clinical trials brings with it a need to consider the impact on Clinical Supply Chain Management.

Almac’s latest edition of its Clinical Supply Knowledge Share eBook series delves into the evolving role of Supply Chain Management, focusing on market demands, the challenges, the physical and digital Clinical Supply Chain, supporting technologies and Almac’s solutions.

Driving clinical trial speed and compliance

With the higher volumes of data that exist in today’s accelerated clinical trials, having an Interactive Response Technology (IRT) partner who understands the challenges of managing this data and how to properly support a regulatory submission is critical.

As the go-to partner for complex studies, Almac Clinical Technologies was the first-ever IRT provider to be audited by the FDA in support of a client’s submission. This article, which is avaiable on Almac Clinical University, will reveal what FDA auditors recognised as the catalyst for reducing trial issues and improving control and predictability.

Almac Diagnostics launch new website – complimentary webinar download

Almac Diagnostics recently launched its new website highlighting its unique Customised Companion Diagnostics (CDx) approach for Pharma and Biotech companies. The website has a wide range of new content on Almac Diagnostic's CDx capabilities, state-of-the art laboratories & platforms and specialist supporting services. There is also a bespoke section detailing its R&D product pipeline of both predictive and prognostic assays.

We are also pleased to announce that Almac Diagnostic's latest Webinar on ‘Next Generation Sequencing Panels – From patient selection to CDx’, by Dr Cheryl McFarlane, Operations Manager, is available to download now. 

Webinar Highlights:

• Development & analytical validation of NGS panels
• Benefits of NGS Panels for Subject Selection
• NGS Panel Case Studies
• CDx Development & Regulatory Considerations 

UPCOMING EVENTS